Peter Dini
T: (203) 286-5366
Intellectual Property

Suffolk University Law School (Intellectual Property Law) (1999-2003)

Harvard Medical School (HHMI Postdoctoral Fellow) (1994-1997)

Stanford Medical School (Tumor Biology Postdoctoral Fellow) (1993-1994)

State University of New York at Stony Brook, Ph.D. (Molecular Biology) (1993), M.A. (1988)

State University of New York at Albany, B.S. (Biology / Chemistry) (1985)



United States Court of Appeals for the Federal Circuit

United States Supreme Court

United States Patent and Trademark Office

Peter Dini

Peter’s practice focuses on assisting clients in life science industries with the creation and monetization of intellectual property assets in a wide array of technologies, which include gene therapy, RNA medicines, antibody engineering, immuno-oncology, antibodies, T-cell therapies, antibody drug conjugates, stem cells, gene libraries / sequencing, manufacturing, dosing, biomarkers, diagnostics, devices, and small molecules.

For over 15 years, Peter, as both in-house intellectual property counsel and in private practice, has combined his technical knowledge with his command of patent law to clearly convey complex subject matter to obtain and extend intellectual property rights for his clients.

Prior to joining Farber LLC, Peter held positions as an in-house Senior IP Counsel at large multinational companies, such as Abbvie / Abbott, as well as, at emerging companies, such as Sorrento Therapeutics and Advanced Proteome Therapeutics. Peter also has experience in private practice, rising from a technical specialist to an associate and ultimately to equity partner at the law firm of Lahive & Cockfield.

Peter received his J.D. from Suffolk University Law School (2003) and his Ph.D. in microbiology from SUNY Stony Brook (1993). In addition, he served as a Post Doctoral Fellow at Stanford University (1993-1994) and at Harvard Medical School (1994-1997). He is admitted to practice in Massachusetts, the Court of Appeals for the Federal Circuit, the Supreme Court of the United States, and the United States Patent and Trademark Office.


Abbott– performed original FTO searches for the commercial launch of the first fully human antibody Humira.

AbbVie – identified an underappreciated dosing patent application and provided the patent strategy to assist in Humira’s product life cycle management.

ESBAtech – prepared platform patent application directed to soluble immunobinders for topically treating eye disease that positioned the company to be acquired by Alcon for 589 million USD.

Sorrento – restructured the company patent estate, prepared 11 new patent applications, and managed 12 separate patent portfolios (~150 cases) to position the company for a 150 million USD money raise.